Wisconsin Capital Management LLC Trims Position in Novo Nordisk A/S (NYSE:NVO)

Wisconsin Capital Management LLC cut its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 5.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 63,179 shares of the company's stock after selling 3,850 shares during the quarter. Novo Nordisk A/S comprises approximately 3.0% of Wisconsin Capital Management LLC's investment portfolio, making the stock its 12th biggest position. Wisconsin Capital Management LLC's holdings in Novo Nordisk A/S were worth $5,435,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of NVO. Victory Capital Management Inc. increased its stake in Novo Nordisk A/S by 58.5% during the 4th quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock worth $5,410,000 after buying an additional 23,223 shares during the period. Norman Fields Gottscho Capital Management LLC raised its holdings in shares of Novo Nordisk A/S by 45.3% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company's stock valued at $5,482,000 after purchasing an additional 19,870 shares in the last quarter. Bryn Mawr Capital Management LLC grew its stake in shares of Novo Nordisk A/S by 358.8% during the fourth quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company's stock worth $3,346,000 after purchasing an additional 30,420 shares in the last quarter. Versant Capital Management Inc purchased a new position in Novo Nordisk A/S in the fourth quarter valued at $86,000. Finally, Talbot Financial LLC purchased a new stake in Novo Nordisk A/S during the 4th quarter worth about $4,066,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock traded down $1.16 during trading hours on Thursday, reaching $67.08. 8,818,417 shares of the stock were exchanged, compared to its average volume of 5,606,078. Novo Nordisk A/S has a 52-week low of $66.88 and a 52-week high of $148.15. The stock has a market cap of $301.04 billion, a P/E ratio of 20.39, a P/E/G ratio of 0.90 and a beta of 0.42. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The firm's 50 day moving average is $81.64 and its 200 day moving average is $97.47.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a $0.7874 dividend. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S's dividend payout ratio (DPR) is 47.72%.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on NVO shares. Morgan Stanley began coverage on Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an "equal weight" rating on the stock. BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research report on Monday, December 23rd. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. Finally, StockNews.com downgraded Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a report on Friday, March 21st. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.